[1] 梁建伟, 王菁,孙雪琴.择期PCI与急诊PCI治疗急性心肌梗死的效果比较[J]. 临床医学, 2021. 41(3): 53-55. [2] Jeong HS, Hong SJ, Cho SA, et al.COMPARISON of TICAGRELOR VERSUS PRASUGREL for INFLAMMATION, VASCULAR FUNCTION AND CIRCULATING ENDOTHELIAL PROGENITOR CELLS IN DIABETIC PATIENTS WITH NON-ST ELEVATION ACUTE CORONARY SYNDROME (NSTE-ACS) REQUIRING CORONARY STENTING: PROSPECTIVE, RANDOMIZED, CROSSOVER TRIAL[J]. Journal of the American College of Cardiology, 2018. 71(11): A2661-A2661. [3] Khan AR, Golwala H, Tripathi A, et al.Impact of total occlusion of culprit artery in acute non-ST elevation myocardial infarction: a systematic review and meta-analysis[J]. European heart journal, 2017. 38(41): 3082-3089. [4] Thorsten R, KR A.The "no-reflow" phenomenon: basic science and clinical correlates[J]. Heart (British Cardiac Society), 2002. 87(2): 162-168. [5] Govindan NR, Jayaprasad N, Madhavan S, et al.Predictors and prognosis of no-reflow during primary percutaneous coronary intervention[J]. Proceedings (Baylor University. Medical Center), 2019,32(1): 30-33. [6] Magro M, Nauta ST, Simsek C, et al.Usefulness of the SYNTAX Score to Predict “No Reflow” in Patients Treated With Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction[J]. The American Journal of Cardiology, 2012, 109(5): 601-606. [7] Oikonomou E, Mourouzis K, Vogiatzi G, et al.Coronary Microcirculation and the No-reflow Phenomenon[J]. Current pharmaceutical design,2018, 24(25): 2934-2942. [8] Kaur G,Baghdasaryan P, Natarajan B, et al, Pathophysiology, Diagnosis, and Management of Coronary No-Reflow Phenomenon[J]. International Journal of Angiology, 2021, 30(1): 15-21. [9] 刘远良,李彪,蒋作锋,等. 半剂量与标准剂量替罗非班对中国老年急性冠状动脉综合征患者介入治疗的疗效及安全性分析:一项Meta分析[J]. 临床荟萃, 2021, 36(11): 965-971. [10] 任琳, 王文广, 王倩,等.半量替罗非班在老年急性心肌梗死急诊经皮冠状动脉介入治疗的疗效和安全性[J]. 中华老年心脑血管病杂志, 2014, 16(1): 32-35. [11] 刘惠良, 王学超, 王立立,等, 冠状动脉内注射替罗非班与静脉注射替罗非班对急诊PCI患者疾病转归的比较研究[J]. 中国循证心血管医学杂志, 2019, 11(9): 1085-1088. |